Coloplast B

Coloplast names Gavin Wood, a Johnson & Johnson veteran, as CEO – a strategic move to boost product pipeline, market reach and operational efficiency in medical technology.

Coloplast A/S thrives amid market volatility, backed by robust finances, a diversified product portfolio, and strategic moves like the Kerecis deal.

Coloplast B’s share price has declined due to downward revisions from leading financial institutions, but the company’s strategic overhaul and solid fundamentals suggest it remains well-positioned for long-term growth.